NewAmsterdam Pharma (NASDAQ:NAMS) Rating Lowered to “Sell” at Wall Street Zen

NewAmsterdam Pharma (NASDAQ:NAMS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

NAMS has been the topic of a number of other research reports. Royal Bank Of Canada boosted their target price on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. The Goldman Sachs Group raised their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday. Needham & Company LLC lifted their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Trading Up 2.7%

NAMS stock opened at $35.58 on Friday. The stock has a market capitalization of $4.03 billion, a P/E ratio of -20.57 and a beta of 0.06. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $42.00. The firm has a 50-day moving average price of $33.97 and a 200-day moving average price of $32.54.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. As a group, equities analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In related news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $199,500.00. Following the sale, the insider directly owned 73,481 shares in the company, valued at $2,443,243.25. This represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Louise Frederika Kooij sold 32,612 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total transaction of $1,037,061.60. Following the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $774,425.40. The trade was a 57.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 298,647 shares of company stock worth $10,236,050 in the last quarter. Corporate insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently bought and sold shares of the company. Empowered Funds LLC acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at $85,000. XTX Topco Ltd raised its position in shares of NewAmsterdam Pharma by 1,714.1% in the 4th quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock worth $4,823,000 after acquiring an additional 129,913 shares in the last quarter. Virtus Investment Advisers LLC raised its position in shares of NewAmsterdam Pharma by 32.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock worth $251,000 after acquiring an additional 1,731 shares in the last quarter. Twinbeech Capital LP acquired a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at about $961,000. Finally, Millennium Management LLC bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at about $8,931,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.